Joint EU-UK pharmaceutical industry response to Specialised Committee outcome

9 November 2020

Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines

5 November 2020

Open letter from Medicines for Europe Executive on the upcoming EU pharmaceutical strategy

20 October 2020

Statement from the President: Now or never: pragmatism & ambition needed in EU pharma strategy to deliver on Europe’s medicines manufacturing

7 October 2020

Berlin, 07 October 2020, speaking at ‘For a Healthy Europe’, […]

IGBA: Global Roadmap for Tailored Clinical Biosimilar Development: Instrumental for Sustainable Access to Biologics

24 September 2020

Joint press statement of European Pharmaceutical industry associations

17 September 2020

Decisive action on medicines shortages should be included in pharmaceutical and industrial strategies

17 September 2020

COVID-19 a lightning rod for major overhaul of EU pharmaceutical policy

9 July 2020

Urgent call for a structured industry-EU dialogue on reform The […]

IQVIA Institute Scorecards show biosimilar medicines offer win for patients, policymakers and healthcare systems across Europe

30 June 2020

Good biosimilar medicine policies balance the benefits of multi-source competition, […]

EU Pharmaceutical Strategy Roadmap: high time to improve patient access to medicines and to apply the lessons from Covid19

4 June 2020